治疗前18F-FDG PET/CT参数在预测非地方性EBV DNA相关鼻咽癌患者接受IMRT和化疗后结局中的作用
回顾性纳入49例接受IMRT±化疗的非转移性非地方性EBV DNA相关鼻咽癌患者,评估治疗前原发灶及颈部淋巴结SUVmax、SUVmean、MTV和TLG与DFS、OS的关系。中位随访55个月,原发灶SUVmax≥18.8 g/ml和TLG≥203.1 g为OS较差的显著预后因素,IVB期和EBV DNA载量≥3493 copies/ml与DFS降低显著相关。PET参数与血浆EBV DNA载量无相关性。
要点
- 原发灶SUVmax≥18.8 g/ml和TLG≥203.1 g与更差OS显著相关。
- IVB期和EBV DNA载量≥3493 copies/ml与更低DFS显著相关。
- PET代谢参数与血浆EBV DNA载量之间未发现相关性。
核心结论
- 即使在本有限系列中,数据提示原发灶SUVmax、SUVmean和TLG可预测非地方性区域鼻咽癌患者的不良结局,作者设想其可用于细化预后分层。
研究设计与样本
- 回顾性研究,纳入160例连续非转移性鼻咽癌患者中49例在本机构接受全身18F-FDG PET/CT分期且随访至少12个月者,患者接受根治性IMRT±化疗。
诊断标准与关键数值
- 原发灶SUVmax≥18.8 g/ml为OS较差的显著预后因素。
- 原发灶TLG≥203.1 g为OS较差的显著预后因素。
- IVB期与更低的DFS显著相关。
- EBV DNA载量≥3493 copies/ml与更低的DFS显著相关。
临床应用与阅片要点
- 作者设想原发灶SUVmax、SUVmean和TLG可用于细化鼻咽癌患者的预后分层。
局限性
- 原文自述为有限系列(limited series)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the prognostic role of pretreatment 18F-FDG PET/CT metabolic parameters in non-endemic Epstein-Barr Virus (EBV DNA)-related nasopharyngeal cancer (NPC) patients treated with curative intensity-modulated radiation therapy (IMRT) with or without chemotherapy (CHT).
MATERIALS/METHODS: We retrospectively reviewed clinical data of 160 consecutive non-metastatic NPC patients who received IMRT with or without CHT. Forty-nine out of 160 patients that underwent whole body 18F-FDG PET/CT at our institution for disease staging with a minimum follow-up to 12 months were included in this study. We evaluated the relationship between maximum and mean standardized uptake values (SUVmax and SUVmean, respectively), metabolic tumor volume and total lesion glycolysis (TLG) of primary tumor and cervical lymph nodes with disease-free survival (DFS) and overall survival (OS). We also investigated the prognostic role of clinical variables such as age, disease stage, plasma EBV DNA load (copies/ml), gross tumor volume of primary tumor and lymph nodes.
RESULTS: Median follow-up was 55 months. Two- and 5-year OS were 95.8% and 90.5%, respectively, while DFS was 83.4% at both time points. SUVmax of primary tumor ≥ 18.8 g/ml and primary tumor TLG ≥ 203.1 g were significant prognostic factors of worse OS. Furthermore, stages IVB and EBV DNA load ≥ 3493 copies/ml were significantly associated with lower DFS. No correlation was found between PET parameters and plasma EBV DNA load.
CONCLUSION: Even in a limited series, our data suggested that SUVmax, SUVmean and TLG of primary tumor could predict a poor outcome in NPC patients also in non-endemic area hypothesizing their use for refinement of prognostication.
引用
- Alessi A, Lorenzoni A, Cavallo A, et al. Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. Radiol Med. 2018. PMID: 30560502. doi:10.1007/s11547-018-0980-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。